Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections

There has been greater interest in developing additional antimicrobial agents due to the increasing health care costs and resistance resulting from bacterial pathogens to currently available treatment options. Gram-negative organisms including Enterobacteriaceae and Pseudomonas aeruginosa are some o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hidalgo, Jose A, Vinluan, Celeste M, Antony, Nishaal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970634/
https://www.ncbi.nlm.nih.gov/pubmed/27528799
http://dx.doi.org/10.2147/DDDT.S110946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970634/
https://www.ncbi.nlm.nih.gov/pubmed/27528799
http://dx.doi.org/10.2147/DDDT.S110946

Ejemplares similares